将丙磺舒重新用于抑制 SARS-CoV-2、流感病毒和呼吸道合胞病毒（RSV）复制。
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication.
机构信息
Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
TrippBio, Inc., Jacksonville, FL 32256, USA.
出版信息
Viruses. 2022 Mar 15;14(3):612. doi: 10.3390/v14030612.
Abstract
Viral replication and transmissibility are the principal causes of endemic and pandemic disease threats. There remains a need for broad-spectrum antiviral agents. The most common respiratory viruses are endemic agents such as coronaviruses, respiratory syncytial viruses, and influenza viruses. Although vaccines are available for SARS-CoV-2 and some influenza viruses, there is a paucity of effective antiviral drugs, while for RSV there is no vaccine available, and therapeutic treatments are very limited. We have previously shown that probenecid is safe and effective in limiting influenza A virus replication and SARS-CoV-2 replication, along with strong evidence showing inhibition of RSV replication in vitro and in vivo. This review article will describe the antiviral activity profile of probenecid against these three viruses.
摘要
病毒复制和传播性是地方性和大流行疾病威胁的主要原因。目前仍然需要广谱抗病毒药物。最常见的呼吸道病毒是地方性病原体，如冠状病毒、呼吸道合胞病毒和流感病毒。尽管 SARS-CoV-2 和一些流感病毒有疫苗可用，但有效的抗病毒药物却很少，而 RSV 既没有疫苗，治疗方法也非常有限。我们之前已经证明丙磺舒在限制甲型流感病毒复制和 SARS-CoV-2 复制方面是安全有效的，并且有强有力的证据表明丙磺舒可以抑制 RSV 在体外和体内的复制。这篇综述文章将描述丙磺舒对这三种病毒的抗病毒活性特征。
相似文献
1
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication.将丙磺舒重新用于抑制 SARS-CoV-2、流感病毒和呼吸道合胞病毒（RSV）复制。
Viruses. 2022 Mar 15;14(3):612. doi: 10.3390/v14030612.
2
Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication.丙磺舒抑制呼吸道合胞病毒（RSV）复制。
Viruses. 2022 Apr 27;14(5):912. doi: 10.3390/v14050912.
3
Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.他普司他汀是广谱的人类主要呼吸道病毒抑制剂：冠状病毒、呼吸道合胞病毒和甲型流感病毒。
Viruses. 2021 Feb 3;13(2):234. doi: 10.3390/v13020234.
4
Triazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).三氮唑核苷可能是对抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的新希望。
Ceska Slov Farm. 2021 Spring;70(1):18-25.
5
4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.4'-氟尿苷是一种口服抗病毒药物，可阻断呼吸道合胞病毒和 SARS-CoV-2 的复制。
Science. 2022 Jan 14;375(6577):161-167. doi: 10.1126/science.abj5508. Epub 2021 Dec 2.
6
Evaluation of Three Multiplex Real-time Reverse Transcription PCR Assays for Simultaneous Detection of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Virus in Nasopharyngeal Swabs.评价三种多重实时逆转录聚合酶链反应检测试剂盒在鼻咽拭子标本中同时检测新型冠状病毒、甲型/乙型流感病毒和呼吸道合胞病毒的效果。
J Korean Med Sci. 2021 Dec 13;36(48):e328. doi: 10.3346/jkms.2021.36.e328.
7
Antiviral Potential of Azelastine against Major Respiratory Viruses.阿佐斯汀抑制主要呼吸道病毒的抗病毒潜力。
Viruses. 2023 Nov 23;15(12):2300. doi: 10.3390/v15122300.
8
[Respiratory viral infections : Under special consideration of severe acute respiratory syndrome coronavirus 2 and influenza viruses].[呼吸道病毒感染：特别考虑严重急性呼吸综合征冠状病毒2和流感病毒]
Med Klin Intensivmed Notfmed. 2023 Sep;118(6):445-453. doi: 10.1007/s00063-023-01050-7. Epub 2023 Aug 29.
9
Recovery from Triple Infection with SARS-CoV-2, RSV and Influenza virus: A case report.SARS-CoV-2、RSV 和流感病毒三重感染的康复：一例报告。
J Infect Public Health. 2023 Jul;16(7):1045-1047. doi: 10.1016/j.jiph.2023.05.001. Epub 2023 May 4.
10
Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus.SARS-CoV-2、流感病毒和呼吸道合胞病毒引起的社区获得性肺炎中的细菌合并感染。
BMC Infect Dis. 2022 Jan 31;22(1):108. doi: 10.1186/s12879-022-07089-9.
引用本文的文献
1
The MAPK Response to Virus Infection Is Modified by Probenecid.丙磺舒可改变丝裂原活化蛋白激酶对病毒感染的反应。
Curr Issues Mol Biol. 2025 Apr 2;47(4):246. doi: 10.3390/cimb47040246.
2
Influenza a Virus Inhibition: Evaluating Computationally Identified Cyproheptadine Through In Vitro Assessment.甲型流感病毒抑制作用：通过体外评估对计算鉴定出的赛庚啶进行评价。
Int J Mol Sci. 2025 Jun 21;26(13):5962. doi: 10.3390/ijms26135962.
3
Pharmacological mechanisms of probenecid for SARS-CoV-2 and RSV co-infection: findings of system pharmacology, molecular docking, molecular dynamics simulation, and structure-activity relationship.丙磺舒治疗新型冠状病毒肺炎和呼吸道合胞病毒合并感染的药理机制：系统药理学、分子对接、分子动力学模拟及构效关系研究结果
Front Microbiol. 2025 Apr 30;16:1552603. doi: 10.3389/fmicb.2025.1552603. eCollection 2025.
4
Immunological insights into the re-emergence of human metapneumovirus.对人偏肺病毒再次出现的免疫学见解。
Curr Opin Immunol. 2025 Jun;94:102562. doi: 10.1016/j.coi.2025.102562. Epub 2025 May 12.
5
Probenecid Inhibits NLRP3 Inflammasome Activity and Mitogen-Activated Protein Kinases (MAPKs).丙磺舒抑制NLRP3炎性小体活性和丝裂原活化蛋白激酶（MAPKs）。
Biomolecules. 2025 Apr 1;15(4):511. doi: 10.3390/biom15040511.
6
Comparative study of the effects of baicalin and probenecid on microRNA expression profiles in porcine aortic vascular endothelial cells infected by Glaesserella parasuis.黄芩苷与丙磺舒对副猪嗜血杆菌感染的猪主动脉血管内皮细胞中微小RNA表达谱影响的比较研究
BMC Vet Res. 2025 Apr 2;21(1):237. doi: 10.1186/s12917-025-04702-2.
7
Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice.丙磺舒在体外和 BALB/c 小鼠体内抑制人偏肺病毒（HMPV）复制。
Viruses. 2024 Jul 6;16(7):1087. doi: 10.3390/v16071087.
8
Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice.丙磺舒在体外和小鼠体内抑制甲型流感病毒（H5N1）和甲型流感病毒（H7N9）。
Viruses. 2024 Jan 19;16(1):152. doi: 10.3390/v16010152.
9
Antiviral Activity of Probenecid and Oseltamivir on Influenza Virus Replication.丙磺舒和奥司他韦对流感病毒复制的抗病毒活性。
Viruses. 2023 Nov 30;15(12):2366. doi: 10.3390/v15122366.
10
Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19.广谱宿主导向抗病毒药物的筛选：从丙磺舒治疗 COVID-19 看开发经验。
Viruses. 2023 Nov 14;15(11):2254. doi: 10.3390/v15112254.
本文引用的文献
1
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.三种新型口服抗病毒药物（莫努匹韦、氟伏沙明和帕罗韦德）治疗 COVID-19 的疗效和安全性：一项荟萃分析。
Ann Med. 2022 Dec;54(1):516-523. doi: 10.1080/07853890.2022.2034936.
2
Pathological sequelae of long-haul COVID.长新冠的病理后遗症。
Nat Immunol. 2022 Feb;23(2):194-202. doi: 10.1038/s41590-021-01104-y. Epub 2022 Feb 1.
3
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.瑞德西韦、莫努匹韦和奈玛特韦仍对 SARS-CoV-2 奥密克戎和其他关注变体保持活性。
Antiviral Res. 2022 Feb;198:105252. doi: 10.1016/j.antiviral.2022.105252. Epub 2022 Jan 24.
4
COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021.COVID-19 发病率和死亡率在有和没有加强针的未接种和完全接种成年人中，在德尔塔和奥密克戎变体出现期间-25 个美国司法管辖区，2021 年 4 月 4 日至 12 月 25 日。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):132-138. doi: 10.15585/mmwr.mm7104e2.
5
Review on molnupiravir as a promising oral drug for the treatment of COVID-19.关于莫努匹拉韦作为一种有前景的治疗新冠肺炎口服药物的综述。
Med Chem Res. 2022;31(2):232-243. doi: 10.1007/s00044-021-02841-3. Epub 2022 Jan 3.
6
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.关于具有治疗 SARS-CoV-2（COVID-19）潜力的药物的最新进展。
Drug Resist Updat. 2021 Dec;59:100794. doi: 10.1016/j.drup.2021.100794. Epub 2021 Dec 9.
7
A National Strategy for the "New Normal" of Life With COVID.应对新冠疫情下“新常态”生活的国家战略。
JAMA. 2022 Jan 18;327(3):211-212. doi: 10.1001/jama.2021.24282.
8
Environmental Factors Influencing COVID-19 Incidence and Severity.环境因素对 COVID-19 发病率和严重程度的影响。
Annu Rev Public Health. 2022 Apr 5;43:271-291. doi: 10.1146/annurev-publhealth-052120-101420. Epub 2022 Jan 4.
9
Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 - Six Hospitals, United States, July-August 2021.2021 年 7-8 月，美国六家医院收治的<18 岁儿童和青少年 COVID-19 患者的特征和临床结局。
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1766-1772. doi: 10.15585/mmwr.mm705152a3.
10
Immunopathology of RSV: An Updated Review.呼吸道合胞病毒的免疫病理学：最新综述。
Viruses. 2021 Dec 10;13(12):2478. doi: 10.3390/v13122478.
Zotero 插件